Yale Cancer Center | Strategic Alliance Partners

January 11, 2020

Mario Sznol, MD, discusses the adverse events that can occur from nivolumab in combination with ipilimumab for patients with melanoma.

January 03, 2020

Mario Sznol, MD, discusses the management of patients with melanoma who progress on immune checkpoint inhibitors.

December 29, 2019

PD-L1-high status, determined via 3 separate immunohistochemistry assays, and blood tumor mutational burden strongly favored atezolizumab over platinum-based chemotherapy and supports the PD-L1 inhibitor as a first-line treatment option in patients with advanced non–small cell lung cancer.

November 28, 2019

Timil Patel, MD, discusses an optimal sequencing strategy in rectal cancer.

August 03, 2019

Sarah B. Goldberg, MD, MPH, discusses the combination of immunotherapy and targeted therapy for the treatment of patients with oncogene-driven lung cancer.

June 06, 2019

James B. Yu, MD, associate professor, therapeutic oncology, director, Prostate and Genitourinary Cancer Radiotherapy Program, Yale Cancer Center, discusses drawbacks of radiation therapy in prostate cancer.

May 22, 2019

Mario Sznol, MD, professor of medicine, co-director, Cancer Immunology Program, co-director, Yale SPORE in Skin Cancer, Yale Cancer Center, discusses factors to consider when combining VEGF TKIs with immunotherapy in renal cell carcinoma (RCC).

May 09, 2019

Mario Sznol, MD, professor of medicine, co-director, Yale SPORE in Skin Cancer, Yale Cancer Center, discusses patient selection for combination therapy in metastatic renal cell carcinoma.

April 29, 2019

Barbara Burtness, MD, professor of Medicine (Medical Oncology) Disease Aligned Research Team Leader, Head and Neck Cancers Program co-director, Developmental Therapeutics Research Program of Yale Cancer Center, discusses the use of biomarkers in metastatic head and neck squamous cell carcinoma.

April 02, 2019

Sarah B. Goldberg, MD, MPH, assistant professor of medicine, Yale School of Medicine and Yale Cancer Center, discusses the diagnosis of patients with mesothelioma.

March 30, 2019

Barbara Burtness, MD, professor of Medicine (Medical Oncology); Disease Aligned Research Team Leader, Head and Neck Cancers Program; co-director, Developmental Therapeutics Research Program; of Yale Cancer Center, discusses the promise of frontline pembrolizumab in the treatment of patients with metastatic head and neck squamous cell carcinoma.

March 22, 2019

Mario Sznol, MD, professor of medicine, co-director, Yale SPORE in Skin Cancer, Yale Cancer Center, discusses unanswered questions with immunotherapy in the treatment of patients with renal cell carcinoma.

March 20, 2019

Roy Decker, MD, PhD, associate professor of Therapeutic Radiology, Yale Cancer Center, discusses traditional roles of radiation therapy in the treatment of patients with lung cancer.

March 13, 2019

Anees B. Chagpar, MD, FACS, associate professor, Department of Surgery, Yale School of Medicine, assistant director, Global Oncology, Yale Comprehensive Cancer Center, discusses the management of the axilla in breast cancer.

February 21, 2019

Sarah B. Goldberg, MD, MPH, an assistant professor of medicine at the Yale School of Medicine and Yale Cancer Center, discusses strategies for managing central nervous system metastases in patients with oncogene-driven non–small cell lung cancer.

February 18, 2019

Sarah B. Goldberg, MD, MPH, sheds light on the complex treatment paradigm for patients with lung cancer who have central nervous system metastases and highlights emerging treatment strategies for those with mesothelioma.

February 14, 2019

Roy Decker, MD, PhD, associate professor of Therapeutic Radiology, Yale Cancer Center, discusses common adverse events associated with radiation therapy in the treatment of patients with lung cancer.

February 06, 2019

Sarah B. Goldberg, MD, MPH, an assistant professor of medicine at the Yale School of Medicine and Yale Cancer Center, discusses treatment strategies for patients with non–small cell lung cancer that develop central nervous system metastases.

December 10, 2018

Although he held a longtime fascination with space exploration to the moon and Mars, Daniel P. Petrylak, MD, took a different path and broke new ground in another frontier: genitourinary oncology.

December 01, 2018

Barbara Burtness, MD, professor of medicine, Yale Cancer Center, discusses the benefit of pembrolizumab (Keytruda) as a treatment for patients with recurrent metastatic head and neck squamous cell carcinoma.